Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 3
1991 3
1992 3
1993 3
1994 5
1995 4
1996 6
1997 2
1998 6
1999 4
2000 3
2001 3
2002 1
2003 2
2004 7
2005 2
2006 2
2007 2
2008 3
2009 7
2010 4
2011 3
2012 5
2013 3
2014 4
2015 6
2016 4
2017 3
2018 5
2019 10
2020 5
2021 6
2022 8
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
In reply.
Feiten S, Dünnebacke J, Weide R. Feiten S, et al. Among authors: weide r. Dtsch Arztebl Int. 2015 Mar 6;112(10):176. doi: 10.3238/arztebl.2015.0176. Dtsch Arztebl Int. 2015. PMID: 25837747 Free PMC article. No abstract available.
A Mediator-cohesin axis controls heterochromatin domain formation.
Haarhuis JHI, van der Weide RH, Blomen VA, Flach KD, Teunissen H, Willems L, Brummelkamp TR, Rowland BD, de Wit E. Haarhuis JHI, et al. Among authors: van der weide rh. Nat Commun. 2022 Feb 8;13(1):754. doi: 10.1038/s41467-022-28377-7. Nat Commun. 2022. PMID: 35136067 Free PMC article.
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry.
Riecke K, Müller V, Neunhöffer T, Park-Simon TW, Weide R, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Wuerstlein R, Denkert C, Decker T, Fehm T, Nekljudova V, Rey J, Loibl S, Laakmann E, Witzel I. Riecke K, et al. Among authors: weide r. ESMO Open. 2023 Jun;8(3):101213. doi: 10.1016/j.esmoop.2023.101213. Epub 2023 Apr 17. ESMO Open. 2023. PMID: 37075697 Free PMC article.
Interventional MR: vascular applications.
Smits HF, Bos C, van der Weide R, Bakker CJ. Smits HF, et al. Among authors: van der weide r. Eur Radiol. 1999;9(8):1488-95. doi: 10.1007/s003300050875. Eur Radiol. 1999. PMID: 10525856 Review.
[Immunoglobulins in PID, SID and neurological autoimmune disease].
Borte M, Baumann U, Pittrow D, Hensel M, Fasshauer M, Huscher D, Reiser M, Stangel M, Gold R, Kirch W; Liste der aktuell beitragenden Zentren, sortiert nach Postleitzahlen (mindestens ein Patient zum 1.3.2012). Borte M, et al. Dtsch Med Wochenschr. 2012 Mar;137(13):675-80. doi: 10.1055/s-0032-1304844. Epub 2012 Mar 20. Dtsch Med Wochenschr. 2012. PMID: 22434180 Review. German.
135 results